## Surgical Management of Breast Cancer — Key Principles ### Breast-Conserving Therapy vs Mastectomy **Key Point:** BCT (lumpectomy + radiotherapy) provides equivalent overall survival and disease-free survival compared to mastectomy in early-stage breast cancer (T1–T2, N0–N1). This is the landmark finding from NSABP B-06 and subsequent meta-analyses. ### Axillary Lymph Node Assessment **High-Yield:** SLNB is the standard of care for axillary staging in clinically node-negative (cN0) breast cancer. However, in **clinically node-positive (cN+) disease**, SLNB is **NOT contraindicated** — it can still be performed, particularly in patients who convert to cN0 after neoadjuvant therapy, or in selected cN1 cases where nodal status confirmation is needed. The statement that SLNB is contraindicated in cN+ patients is outdated and incorrect. **Clinical Pearl:** In cN1 disease without neoadjuvant therapy, axillary lymph node dissection (ALND) is typically performed. However, SLNB may be considered in select cases and is not an absolute contraindication. ### Mastectomy Variants **Key Point:** Skin-sparing mastectomy (SSM) preserves the breast skin envelope (except nipple-areola complex) and is preferred when immediate reconstruction is planned, as it provides superior cosmetic outcomes and maintains breast contour. ### Oncoplastic Surgery **High-Yield:** Oncoplastic techniques (volume displacement, reduction, or reshaping) can be safely integrated into BCT to: - Improve cosmesis after lumpectomy - Reduce re-excision rates - Maintain adequate margins without compromising oncological safety | Aspect | BCT | Mastectomy | | --- | --- | --- | | Survival (early stage) | Equivalent | Equivalent | | Recurrence risk | 5–10% (with RT) | 1–2% | | Cosmesis | Good to excellent | Varies with reconstruction | | Radiotherapy | Mandatory | Not routine (except high-risk) | ### Why Option 1 is Incorrect SLNB is **not contraindicated** in clinically node-positive disease. While ALND is the traditional standard in cN+ patients, SLNB can be performed in selected cases (e.g., post-neoadjuvant therapy conversion to cN0, or to confirm nodal status in cN1 disease). Modern guidelines do not list cN+ as an absolute contraindication to SLNB. [cite:AJCC Cancer Staging Manual 8e, NCCN Breast Cancer Guidelines 2023]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.